Induced Pluripotent Stem Cells for Traumatic Spinal Cord Injury

Spinal cord injury (SCI) often leads to mortality and neurological issues. Although treatments have improved, the outcomes are not always ideal. Cell transplantation is a promising therapeutic strategy, but it faces obstacles, including ethical concerns about cell sources. Using iPSCs is appealing as they can be an autologous cell source, avoiding ethical problems linked to other stem cell sources. Plus, iPSCs can turn into different cell types useful for SCI treatment. Common sources for reprogramming include skin cells, blood cells, and fat stem cells. In SCI, iPSCs can become neural precursor cells, neurons, or other supportive cells. These cells can help recovery by replacing damaged cells or changing the environment around the injury.

• 1
  iPSCs can differentiate into neural precursor cells, neural crest cells, neurons, oligodendrocytes, astrocytes, and even mesenchymal stromal cells, offering diverse therapeutic potential for SCI.
• 2
  Different somatic cell types, like fibroblasts, keratinocytes, and cord blood cells, can be used to generate iPSCs, each with varying reprogramming efficiencies and epigenetic considerations.
• 3
  iPSC-derived NPCs have shown promise in preclinical studies, demonstrating the ability to differentiate into neurons and glia, enhance remyelination, promote axon regeneration, and improve behavioral outcomes in SCI models.